ALNY
Alnylam Pharmaceuticals
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: ALNY
- PEG Ratio
As of Jun 23, 2026, ALNY's PEG ratio of 0.19 reflects its valuation relative to its growth rate. This result reflects a P/E ratio of 66.1 measured against EPS growth of 343.6%.
ALNY PEG ratio history
Alnylam Pharmaceuticals PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.79 | 166.38 | 209.6% |
| 2024 | N/A | N/A | 38.1% |
| 2023 | N/A | N/A | 62.2% |
| 2022 | N/A | N/A | -29.2% |
| 2021 | N/A | N/A | 3.5% |
| 2020 | N/A | N/A | 8% |
| 2019 | N/A | N/A | -7.1% |
| 2018 | N/A | N/A | -39.7% |
| 2017 | N/A | N/A | -13.2% |
| 2016 | N/A | N/A | -38.8% |
| 2015 | N/A | N/A | 28.9% |
| 2014 | N/A | N/A | -234.5% |
| 2013 | N/A | N/A | 31.3% |
| 2012 | N/A | N/A | -55.1% |
| 2011 | N/A | N/A | -30.8% |
Alnylam Pharmaceuticals PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.22 | 75.89 | 343.6% |
| Dec 2025 | 0.79 | 166.38 | 209.6% |
| Sep 2025 | 6.06 | 747.54 | 123.4% |
| Jun 2025 | N/A | N/A | -287.5% |
| Mar 2025 | N/A | N/A | 32.2% |
| Dec 2024 | N/A | N/A | 38.1% |
| Sep 2024 | N/A | N/A | 36.5% |
| Jun 2024 | N/A | N/A | 93.5% |
| Mar 2024 | N/A | N/A | 69.6% |
| Dec 2023 | N/A | N/A | 62.2% |
| Sep 2023 | N/A | N/A | 57.9% |
| Jun 2023 | N/A | N/A | -5.4% |
| Mar 2023 | N/A | N/A | -16% |
| Dec 2022 | N/A | N/A | -29.2% |
| Sep 2022 | N/A | N/A | -37% |
ALNY average PEG ratio chart
PEG comparison
With a PEG of 0.19, ALNY ranks lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 0.56, Alnylam Pharmaceuticals's PEG is 66% lower.
ALNY EPS growth
ALNY Price vs fair value
ALNY PEG vs peers
Relative to its peers, ALNY's PEG ratio is below NVS's and REGN's yet above TEVA's.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| TEVA Teva Pharmaceutical Industries Ltd | 0.11 | $38.67B |
| ALNY Alnylam Pharmaceuticals Inc | 0.19 | $38.48B |
| SRPT Sarepta Therapeutics Inc | 0.23 | $1.82B |
| NVS Novartis AG | 2.38 | $292.66B |
| REGN Regeneron Pharmaceuticals Inc | 7.64 | $64.79B |
| ARWR Arrowhead Pharmaceuticals Inc | N/A | $11.25B |
| OPK Opko Health Inc | N/A | $1.1B |
Frequently asked questions
What is Alnylam Pharmaceuticals's PEG ratio?
ALNY has a PEG ratio of 0.19, per Jun 23, 2026 data.
Why is Alnylam Pharmaceuticals's PEG ratio so low?
At 0.19, ALNY's PEG ratio suggests the stock may be undervalued given its growth rate.
How is ALNY's PEG ratio calculated (Alnylam Pharmaceuticals PEG ratio formula)?
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jun 23, 2026, Alnylam Pharmaceuticals carries a PE ratio of 66.1. Earnings grew at 343.6% over the TTM period ending Mar 2026. Applying the formula, this yields a PEG ratio of 0.19. PEG RATIO(0.19) = PE RATIO(66.1) / EPS GROWTH(343.6%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.